Background We assessed the power from the dual PI3K/mTOR inhibitor NVP-BEZ235 (BEZ235) as solitary agent therapy and in conjunction with conventional chemotherapy for thyroid malignancy. Baseline degrees of p-S6 ribosomal proteins (Ser235/236) and p27 correlated with BEZ235 level of sensitivity. Development of 8505C ATC xenograft tumors was inhibited with BEZ235, without the observed toxicity. Mixture… Continue reading Background We assessed the power from the dual PI3K/mTOR inhibitor NVP-BEZ235